Nima Ghasemzadeh1, Abdul Wahab Hritani1, Christine De Staercke2, Danny J Eapen1, Emir Veledar3, Hatem Al Kassem1, Mohamed Khayata1, A Maziar Zafari4, Laurence Sperling1, Craig Hooper2, Viola Vaccarino5, Kreton Mavromatis4, Arshed A Quyyumi6. 1. Emory University School of Medicine, Atlanta, GA, USA. 2. Center for Disease Control and Prevention, Atlanta, GA, USA. 3. Department of Biostatistics, Florida International University, Miami, FL, USA; Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA. 4. Emory University School of Medicine, Atlanta, GA, USA; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA. 5. Emory University School of Medicine, Atlanta, GA, USA; Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA. 6. Emory University School of Medicine, Atlanta, GA, USA. Electronic address: aquyyum@emory.edu.
Abstract
OBJECTIVE: Stromal derived factor-1α/CXCL12 is a chemoattractant responsible for homing of progenitor cells to ischemic tissues. We aimed to investigate the association of plasma CXCL12 with long-term cardiovascular outcomes in patients with coronary artery disease (CAD). METHODS: 785 patients aged: 63 ± 12 undergoing coronary angiography were independently enrolled into discovery (N = 186) and replication (N = 599) cohorts. Baseline levels of plasma CXCL12 were measured using Quantikine CXCL12 ELISA assay (R&D systems). Patients were followed for cardiovascular death and/or myocardial infarction (MI) for a mean of 2.6 yrs. Cox proportional hazard was used to determine independent predictors of cardiovascular death/MI. RESULTS: The incidence of cardiovascular death/MI was 13% (N = 99). High CXCL12 level based on best discriminatory threshold derived from the ROC analysis predicted risk of cardiovascular death/MI (HR = 4.81, p = 1 × 10(-6)) independent of traditional risk factors in the pooled cohort. Addition of CXCL12 to a baseline model was associated with a significant improvement in c-statistic (AUC: 0.67-0.73, p = 0.03). Addition of CXCL12 was associated with correct risk reclassification of 40% of events and 10.5% of non-events. Similarly for the outcome of cardiovascular death, the addition of the CXCL12 to the baseline model was associated with correct reclassification of 20.7% of events and 9% of non-events. These results were replicated in two independent cohorts. CONCLUSION: Plasma CXCL12 level is a strong independent predictor of adverse cardiovascular outcomes in patients with CAD and improves risk reclassification.
OBJECTIVE: Stromal derived factor-1α/CXCL12 is a chemoattractant responsible for homing of progenitor cells to ischemic tissues. We aimed to investigate the association of plasma CXCL12 with long-term cardiovascular outcomes in patients with coronary artery disease (CAD). METHODS: 785 patients aged: 63 ± 12 undergoing coronary angiography were independently enrolled into discovery (N = 186) and replication (N = 599) cohorts. Baseline levels of plasma CXCL12 were measured using Quantikine CXCL12 ELISA assay (R&D systems). Patients were followed for cardiovascular death and/or myocardial infarction (MI) for a mean of 2.6 yrs. Cox proportional hazard was used to determine independent predictors of cardiovascular death/MI. RESULTS: The incidence of cardiovascular death/MI was 13% (N = 99). High CXCL12 level based on best discriminatory threshold derived from the ROC analysis predicted risk of cardiovascular death/MI (HR = 4.81, p = 1 × 10(-6)) independent of traditional risk factors in the pooled cohort. Addition of CXCL12 to a baseline model was associated with a significant improvement in c-statistic (AUC: 0.67-0.73, p = 0.03). Addition of CXCL12 was associated with correct risk reclassification of 40% of events and 10.5% of non-events. Similarly for the outcome of cardiovascular death, the addition of the CXCL12 to the baseline model was associated with correct reclassification of 20.7% of events and 9% of non-events. These results were replicated in two independent cohorts. CONCLUSION: Plasma CXCL12 level is a strong independent predictor of adverse cardiovascular outcomes in patients with CAD and improves risk reclassification.
Authors: Thomas Wurster; Konstantinos Stellos; Michael Haap; Peter Seizer; Tobias Geisler; James Otton; Andreas Indermuehle; Masaki Ishida; Andreas Schuster; Eike Nagel; Meinrad Gawaz; Boris Bigalke Journal: Int J Cardiol Date: 2011-07-06 Impact factor: 4.164
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Anke Burger-Kentischer; Heike Goebel; Rüdiger Seiler; Gustav Fraedrich; Hans E Schaefer; Stefanie Dimmeler; Robert Kleemann; Jürgen Bernhagen; Christian Ihling Journal: Circulation Date: 2002-04-02 Impact factor: 29.690
Authors: Konstantinos Stellos; Harald Langer; Karin Daub; Tanja Schoenberger; Alexandra Gauss; Tobias Geisler; Boris Bigalke; Iris Mueller; Michael Schumm; Iris Schaefer; Peter Seizer; Bjoern F Kraemer; Dorothea Siegel-Axel; Andreas E May; Stephan Lindemann; Meinrad Gawaz Journal: Circulation Date: 2007-12-17 Impact factor: 29.690
Authors: Teresa Infante; Ernesto Forte; Concetta Schiano; Carlo Cavaliere; Carlo Tedeschi; Andrea Soricelli; Marco Salvatore; Claudio Napoli Journal: Am J Transl Res Date: 2017-07-15 Impact factor: 4.060
Authors: Salim S Hayek; Yuri Klyachkin; Ahmed Asfour; Nima Ghasemzadeh; Mosaab Awad; Iraj Hesaroieh; Hina Ahmed; Brandon Gray; Jinhee Kim; Edmund K Waller; Arshed A Quyyumi; Ahmed K Abdel-Latif Journal: Stem Cells Transl Med Date: 2016-10-14 Impact factor: 6.940
Authors: Santhosh Kumar Ghadge; Moritz Messner; Herbert Seiringer; Thomas Maurer; Simon Staggl; Tanja Zeller; Christian Müller; Daniela Börnigen; Wolfgang J Weninger; Stefan H Geyer; Sieghart Sopper; Anne Krogsdam; Gerhard Pölzl; Axel Bauer; Marc-Michael Zaruba Journal: Int J Mol Sci Date: 2021-05-31 Impact factor: 5.923
Authors: Lesley Baerts; Yannick Waumans; Inger Brandt; Wolfgang Jungraithmayr; Pieter Van der Veken; Marc Vanderheyden; Ingrid De Meester Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240
Authors: Muhammad Hammadah; Ayman Samman Tahhan; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Bryan R Kindya; Heval M Kelli; Wesley T O'Neal; Pratik Sandesara; Samaah Sullivan; Zakaria Almuwaqqat; Malik Obideen; Naser Abdelhadi; Ayman Alkhoder; Pratik M Pimple; Oleksiy Levantsevych; Kareem H Mohammed; Lei Weng; Laurence S Sperling; Amit J Shah; Yan V Sun; Brad D Pearce; Michael Kutner; Laura Ward; J Douglas Bremner; Jinhee Kim; Edmund K Waller; Paolo Raggi; David Sheps; Viola Vaccarino; Arshed A Quyyumi Journal: J Am Heart Assoc Date: 2018-02-10 Impact factor: 5.501